-
Taxonomy & unit
-
us-gaap: USD
-
Description
-
Amount of deferred income tax expense (benefit) pertaining to income (loss) from continuing operations.
-
Summary
-
Xeris Biopharma Holdings, Inc. quarterly/annual Deferred Income Tax Expense (Benefit) history and growth rate from 2023 to 2024.
- Xeris Biopharma Holdings, Inc. Deferred Income Tax Expense (Benefit) for the quarter ending March 31, 2024 was $307 K.
- Xeris Biopharma Holdings, Inc. annual Deferred Income Tax Expense (Benefit) for 2023 was -$1.25 M, a 12.3% increase from 2022.
- Xeris Biopharma Holdings, Inc. annual Deferred Income Tax Expense (Benefit) for 2022 was -$1.42 M.
Deferred Income Tax Expense (Benefit), Quarterly (USD)